Evidence map›Paper›PMID 30920880›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.

Yun Chen, Jinjun Ye, Zhengfei Zhu, Weixin Zhao, Jialiang Zhou, Chaoyang Wu, Huarong Tang, Min Fan, Ling Li, Qin Lin and 7 more

5 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04844385 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

TypeinterventionalSponsorSun Yat-sen UniversityRan2021 to 2024Enrolled124ConditionsEsophageal Squamous Cell CarcinomaArmsToripalimab, Paclitaxel-albumin, Nedaplatin, radiation therapy at a total dose 60 Gy, Capecitabine
NCT05944809 phase2completednot on this mapstarted 2023, after this paper: background citation

A Prospective Phase II Study of Prophylactic TPO Combined with Bone Marrow-sparing Intensity-modulated Radiotherapy to Reduce Platelet Inhibition in Patients with Esophageal Cancer Undergoing Concurrent Chemoradiotherapy

TypeinterventionalSponsorJIANYANG WANGRan2023 to 2024Enrolled32ConditionsEsophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy, ThrombocytopeniaArmsrhTPO
NCT06342167 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Concurrent Sintilimab and Radiotherapy With Immunonutrition Support in Esophageal Cancer: A Phase II Multicenter Clinical Trial

TypeinterventionalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2024 to 2026Enrolled57ConditionsLocally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent ChemoradiotherapyArmsRadiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
NCT06912074 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Comparing Hypofractionated Concurrent Chemoradiotherapy Versus Conventional Fractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Open-Label, Randomized Phase II Clinical Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2025 to 2029Enrolled134ConditionsEsophageal Squamous Cell Carcinoma (ESCC)ArmsInduction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurrent Chemotherapy
NCT06960889 active not recruitingnot on this mapstarted 2025, after this paper: background citation

A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

TypeobservationalSponsorNanfang Hospital, Southern Medical UniversityRan2025 to 2027Enrolled500ConditionsEsophageal Cancer (EsC)Armsradiotherapy, Immunotherapy, surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Dose escalation based onRadiation oncology (London, England) · 2022
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Yun Chen1 Fudan University Shanghai Cancer Center, Shanghai, China.
Jinjun Ye2 Jiangsu Cancer Hospital, Nanjing, China.
Zhengfei Zhu1 Fudan University Shanghai Cancer Center, Shanghai, China.
Weixin Zhao1 Fudan University Shanghai Cancer Center, Shanghai, China.
Jialiang Zhou3 Affiliated Hospital of Jiangnan University, Wuxi, China.
Chaoyang Wu4 Zhenjiang First People's Hospital, Zhenjiang, China.
Huarong Tang4 Zhenjiang First People's Hospital, Zhenjiang, China.
Min Fan1 Fudan University Shanghai Cancer Center, Shanghai, China.
Ling Li1 Fudan University Shanghai Cancer Center, Shanghai, China.
Qin Lin5 The First Affiliated Hospital of Xiamen University, Xiamen, China.
Yi Xia6 Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China.
Yunhai Li6 Fudan University Shanghai Cancer Center Minhang Branch Hospital, Shanghai, China.
Jiancheng Li7 Fujian Provincial Cancer Hospital, Fuzhou, China.
Huixun Jia1 Fudan University Shanghai Cancer Center, Shanghai, China.
Saiquan Lu1 Fudan University Shanghai Cancer Center, Shanghai, China.
Zhen Zhang1 Fudan University Shanghai Cancer Center, Shanghai, China.
Kuaile Zhao1 Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis trial aimed to assess the efficacy and safety of the paclitaxel plus fluorouracil regimen versus the cisplatin plus fluorouracil regimen in definitive concurrent chemoradiotherapy (dCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). PATIENTS AND

methodsPatients with locally advanced ESCC were enrolled and randomly assigned to either the paclitaxel plus fluorouracil group or the cisplatin plus fluorouracil group. The patients in the paclitaxel plus fluorouracil group were treated with paclitaxel and fluorouracil one cycle per week in dCRT for five cycles followed by paclitaxel and fluorouracil one cycle per month in consolidation chemotherapy for two cycles. The patients in the cisplatin/5-fluorouracil group were treated with cisplatin and fluorouracil one cycle per month in dCRT for two cycles followed by two cycles in consolidation chemotherapy. The radiotherapy dose was 61.2 Gy delivered in 34 fractions. The primary end point was 3-year overall survival (OS).

resultsFour hundred thirty-six patients with ESCC in six centers were recruited at a 1:1 ratio between April 2012 and July 2015. The median follow-up of the surviving patients was 48.7 months (interquartile range, 42.6-60.9). The 3-year OS was 55.4% in the paclitaxel plus fluorouracil group and 51.8% in the cisplatin plus fluorouracil group (hazard ratio, 0.905 [95% CI, 0.698 to 1.172];

conclusionThe paclitaxel plus fluorouracil regimen did not significantly prolong the OS compared with the standard cisplatin plus fluorouracil regimen in dCRT in patients with locally advanced ESCC.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellChemoradiotherapyChinaCisplatinConsolidation ChemotherapyDisease-Free SurvivalEsophageal NeoplasmsFluorouracilHumansKaplan-Meier EstimateMaleMiddle AgedCisplatinFluorouracilPaclitaxel

Identifiers

PMID30920880
PMCPMC6638596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.